Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001;3 Suppl 2(Suppl 2):S2-S10.

Prostate cancer pathology, screening, and epidemiology

E D Crawford, G J Miller, F Labrie, D Hirano, J Batuello, L M Glodé

Prostate cancer pathology, screening, and epidemiology

E D Crawford et al. Rev Urol. 2001.

Abstract

Recent advances in the understanding of prostate cancer pathology, screening methods, and epidemiology were discussed at the 11th International Prostate Cancer Update. Regarding pathology, Dr. Gary Miller enumerated several factors that lead to the perception of prostate cancer as "unpredictable." These include the disease's multifocal nature, variable progression rates, and the uncertainty regarding the point at which carcinomas metastasize. Screening methods have been the subject of research by the Laval University Prostate Cancer Screening Program since 1988. Dr. Fernand Labrie presented the results of this 10-year study. Dr. Daisaku Hirano presented data from his studies of prostate cancer epidemiology in Japan as compared to the United States. The role of environmental factors, particularly diet, in prostate cancer pathogenesis and development is supported by the increase of the disease in Japan, concurrent with the "westernization" of diet there. Finally, useful information was presented on new computer- and Internet-based diagnostic and research tools.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of serum prostate-specific antigen at first and follow-up visits in 45-80-year-old men.
Figure 2
Figure 2
Distribution of clinical stages of 337 and 215 (327 and 206 staged) prostate cancers diagnosed at first and follow-up screening visits, respectively. Data are expressed as percentage of total number of staged cancers in each group to facilitate comparison.
Figure 3
Figure 3
Summary of data of the Laval University prostate cancer screening program (November 15, 1988 to December 31, 1998).
Figure 4
Figure 4
The trend of new patients with prostate cancer treated in the Nihon University Hospitals and affiliated hospitals between 1995 and 1999.
Figure 5
Figure 5
The trend of clinical stages every 3 years in patients who received radical prostatectomy in the Nihon University, Itabashi Hospital between 1987 and 1998.
Figure 6
Figure 6
User sessions in the first half of 2000 at www.asco.org.
See this image and copyright information in PMC

References

    1. Labrie F. Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support. Prostate. 2000;43:215–222. - PubMed
    1. Prostate Cancer Triallists’ Collaborative Group, authors. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355:1491–1498. - PubMed
    1. Labrie F, Candas B, Cusan L, et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology. 1996;47:212–217. - PubMed
    1. Candas B, Cusan L, Gomez J-L, et al. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate. 2000;45:19–35. - PubMed
    1. Schröder FH, van der Maas P, Beemsterboer P, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. J Natl Cancer Inst. 1998;90:1817–1823. - PubMed

LinkOut - more resources